X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (140) 140
hematology (101) 101
index medicus (96) 96
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (87) 87
female (84) 84
male (80) 80
adult (76) 76
middle aged (76) 76
chronic myelogenous leukemia (74) 74
chronic myeloid leukemia (69) 69
aged (68) 68
imatinib mesylate (68) 68
hemic and lymphatic diseases (64) 64
treatment outcome (64) 64
oncology (62) 62
pyrimidines - therapeutic use (55) 55
imatinib (54) 54
antineoplastic agents - therapeutic use (53) 53
benzamides (52) 52
leukemia, myelogenous, chronic, bcr-abl positive - genetics (51) 51
protein kinase inhibitors - therapeutic use (47) 47
piperazines - therapeutic use (45) 45
adolescent (44) 44
aged, 80 and over (41) 41
fusion proteins, bcr-abl - genetics (37) 37
dasatinib (33) 33
nilotinib (30) 30
leukemia (29) 29
tyrosine kinase inhibitors (29) 29
young adult (29) 29
bcr-abl (27) 27
pyrimidines - administration & dosage (27) 27
chronic myeloid-leukemia (26) 26
therapy (25) 25
follow-up (24) 24
prognosis (24) 24
leukemia, myelogenous, chronic, bcr-abl positive - mortality (23) 23
abridged index medicus (21) 21
antineoplastic agents (21) 21
antineoplastic agents - adverse effects (21) 21
pyrimidines - adverse effects (21) 21
care and treatment (20) 20
disease-free survival (20) 20
follow-up studies (20) 20
piperazines - administration & dosage (19) 19
chronic-phase (18) 18
cml (18) 18
philadelphia chromosome (18) 18
survival rate (18) 18
antimitotic agents (17) 17
antineoplastic agents - administration & dosage (17) 17
hematology, oncology and palliative medicine (17) 17
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (17) 17
resistance (17) 17
survival (17) 17
time factors (17) 17
tyrosine (17) 17
analysis (16) 16
protein-tyrosine kinases - antagonists & inhibitors (16) 16
cancer (15) 15
leukemia, myeloid, chronic-phase - drug therapy (15) 15
protein kinase inhibitors - administration & dosage (15) 15
protein kinase inhibitors - adverse effects (15) 15
drug resistance, neoplasm (14) 14
interferon-alpha (14) 14
molecular response (14) 14
tyrosine kinase (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
bone marrow transplantation (13) 13
leukemia, myelogenous, chronic, bcr-abl positive - therapy (13) 13
mesylate (13) 13
philadelphia-chromosome (13) 13
piperazines - adverse effects (13) 13
recommendations (13) 13
remission induction (13) 13
leukemia, myelogenous, chronic, bcr-abl positive - pathology (12) 12
neoplasms (12) 12
survival analysis (12) 12
thiazoles - therapeutic use (12) 12
chronic phase (11) 11
cytogenetic analysis (11) 11
cytogenetic responses (11) 11
drug resistance, neoplasm - genetics (11) 11
leukemia, myelogenous, chronic, bcr-abl positive - epidemiology (11) 11
management (11) 11
myeloid leukemia (11) 11
retrospective studies (11) 11
bcr-abl1 (10) 10
cell biology (10) 10
drug therapy (10) 10
european leukemianet (10) 10
genetic aspects (10) 10
minimal residual disease (10) 10
tyrosine kinase inhibitor (10) 10
acute lymphoblastic-leukemia (9) 9
benzamides - therapeutic use (9) 9
blast crisis (9) 9
breccia (9) 9
chronic granulocytic-leukemia (9) 9
clinical resistance (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 841 - 851
Summary Background Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid... 
Hematology, Oncology and Palliative Medicine | CHRONIC MYELOGENOUS LEUKEMIA | HALF | THERAPY | ONCOLOGY | MOLECULAR RESPONSES | RECOMMENDATIONS | HARMONIZING CURRENT METHODOLOGY | TYROSINE KINASE INHIBITOR | DISCONTINUATION | BCR-ABL TRANSCRIPTS | Piperazines - administration & dosage | Singapore | Protein-Tyrosine Kinases - metabolism | United States | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Brazil | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Philadelphia Chromosome | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Europe | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Benzamides | Australia | Fusion Proteins, bcr-abl - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Antineoplastic agents | Product development
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 02/2017, Volume 14, Issue 3, pp. 141 - 154
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 612 - 621
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2006, Volume 12, Issue 24, pp. 7374 - 7379
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2005, Volume 23, Issue 18, pp. 4100 - 4109
Journal Article
Blood, ISSN 0006-4971, 2011, Volume 118, Issue 3, pp. 686 - 692
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 6, pp. 872 - 884
Journal Article